Preclinical Imaging (In-VIVO) Market Growth Drivers & Forecast 2033

Preclinical Imaging (In-VIVO) by Application (Oncology, Cardio and Vascular, Neurology, Others), by Types (Equipment, Reagent), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $1.8 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $1.8 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Preclinical Imaging (In-VIVO) Market Overview

Preclinical In-VIVO imaging encompasses non-invasive technologies used to visualize living organisms for drug discovery and development, providing critical translational data before human trials. With the Preclinical Imaging (In-VIVO) market size valued at USD 1.04 billion in 2025, the sector is poised for robust industry expansion, underpinned by a growth outlook of ~7.8% CAGR through 2033. Optical, micro-PET/CT, and high-field MRI platforms are rapidly replacing traditional ex-vivo methods, while AI-driven image analytics compress timelines from weeks to hours. Regulatory pressure to demonstrate early efficacy and safety, combined with biotech funding that surpassed USD 90 billion globally in 2023, fuels a sustained market forecast upswing.

Loading chart…

North America retains the largest revenue share (>40%) thanks to dense CRO clusters and NIH funds exceeding USD 2.5 billion for imaging infrastructure, whereas Asia-Pacific is the fastest-growing region—CAGR >9%—spurred by cost-efficient multi-modal facilities in China and India. Technology shifts toward ultra-high-field (≥9.4 T) MRI and AI-enhanced hybrid systems are reshaping competitive dynamics, compressing scan times and improving throughput. Simultaneously, regulatory harmonization (e.g., FDA-EMA parallel scientific advice) accelerates cross-border trials, but supply-chain constraints in cryogen-free magnets and semiconductor detectors keep procurement lead times at 6–9 months, influencing vendor selection and capital budgeting across academic and pharma labs.

Report Overview

Report Attribute	Details
Market size value in 2025	1.80 million
Revenue forecast in 2033	2.91 million
Growth rate	CAGR of 6.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	PerkinElmer; Bruker Corporation; FUJIFILM Holdings; Mediso; MILabs B.V.; MR Solutions; Aspect Imaging; LI-COR Biosciences; Trifoil Imaging; Miltenyi Biotec
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Market Dynamics for the Preclinical Imaging (In-VIVO) market

Growth Drivers2 items

Biopharma outsourcing to full-service CROs is accelerating demand for high-throughput in-vivo imaging suites, compressing study timelines by 25–30 % and expanding the Preclinical Imaging (In-VIVO) market size beyond traditional academic strongholds.

Next-generation AI-driven optical and PET reconstruction engines now deliver sub-100 µm spatial resolution at scan times <2 min, unlocking longitudinal oncology and neurodegeneration studies that were previously cost-prohibitive and propelling a five-year CAGR uplift of ~2.3 pp in the growth forecast.

Restraints2 items

Capital equipment inflation—up 12–15 % since 2021—has stretched CRO payback periods past 5.5 years, causing sponsors to reallocate budgets toward lower-cost ex-vivo modalities and capping near-term Preclinical Imaging (In-VIVO) market expansion.

Tightening radioisotope supply chains (Mo-99/Tc-99m aging reactors) translate into >20 % price volatility for PET tracers, forcing imaging labs to hedge inventory and compress utilization rates below 70 %.

Opportunities2 items

Rising theranostic pipelines (177Lu, 89Zr, 64Cu) create a hybrid service layer where imaging CROs capture both dosing validation and efficacy readouts, lifting revenue per study by 35 % and expanding addressable Preclinical Imaging (In-VIVO) market size into late-phase translational segments.

Cloud-based, vendor-neutral image repositories are enabling tier-2 CROs in Asia–Pacific to monetize idle scanner capacity via on-demand subscriptions, cutting customer scan cost by >40 % and opening emerging-geography growth forecast upside of 8–9 % CAGR.

Challenges2 items

Fragmented regulatory guidance across FDA, EMA, and PMDA on imaging endpoint validation prolongs study start-up by 4–6 months, delaying revenue recognition and compressing IRRs for imaging CROs.

A crowded supplier landscape (>25 OEMs) coupled with commoditized 3T MRI and µCT platforms has triggered double-digit price erosion, pressuring gross margins below 35 % and intensifying the need for value-based differentiation in the Preclinical Imaging (In-VIVO) market.

Market Segmentation

Loading chart…

Application-level Preclinical Imaging (In-VIVO) segmentation drives demand heterogeneity across the market taxonomy. Oncology dominates, accounting for roughly 38 % of 2023 global instrument revenues because serial imaging of tumor-bearing rodents shortens drug-efficacy timelines and reduces animal counts, translating into direct R&D savings. Neurology follows with a 22 % share; the rise of transgenic Alzheimer’s and Parkinson’s models elevates PET and MRI throughput, while stroke studies fuel high-frequency optical imaging demand. Cardiology (15 %) is propelled by miniaturized ultrasound and MR systems that quantify ejection fraction in mice, indispensable for metabolic-syndrome pipelines. Inflammation & infection (12 %) benefits from dual-modal PET-CT that tracks leukocyte trafficking in real time, a capability valued for autoimmune and sepsis programs. Other applications—including musculoskeletal, diabetes, and toxicology studies—collectively contribute 13 %, yet grow fastest in Asia-Pacific due to outsourcing of safety-assessment work. Each vertical commands distinct imaging frequency, tracer portfolio, and regulatory documentation, shaping vendor pricing power and installed-base loyalty.

The Types dimension refines the Preclinical Imaging (In-VIVO) market taxonomy into modality clusters that map to spatial resolution, penetration depth, and throughput needs. Optical imaging—split into fluorescence and bioluminescence—captures the largest share (≈30 % of 2023 unit sales) because low-cost CCD systems fit high-throughput cancer screens despite limited mm-scale penetration. Micro-MRI, generating 25 % of revenue, commands premium pricing via 50–100 µm isotropic resolution and soft-tissue contrast required for neurodegeneration studies, though throughput is <3 mice h⁻¹. Micro-CT, at 20 %, delivers sub-10 µm bone morphology but necessitates low-dose protocols to meet IACUC limits, spurring dual-energy upgrades. Micro-PET and Micro-SPECT (10 % and 8 % respectively) trade resolution (1–2 mm) against picomolar tracer sensitivity, with PET gaining share in early oncology target engagement while SPECT persists for inflammation work owing to lower infrastructure cost. Ultrasound (5 %) provides real-time hemodynamics at 30 µm resolution, ideal for cardiovascular phenotyping. Other modalities—including photoacoustic and hybrid MR-PET—occupy 2 %, yet attract venture funding for multimodal neuro-oncology applications.

Preclinical Imaging (In-VIVO) Segmentation Breakdown8 items

Application

Oncology

Cardio and Vascular

Neurology

Others

Types

Equipment

Reagent

Regional Insights

Loading chart…

North America retains its dominant 41 % share of the Preclinical Imaging (In-VIVO) market growth, propelled by the NIH’s US $45 bn FY-24 budget, a dense cluster of CROs with GLP-accredited imaging suites, and immediate uptake of AI-enabled multimodal systems. Europe (28 %) leverages Horizon Europe subsidies, the forthcoming EMA 3Rs guidance, and a robust network of translational imaging centers that accelerate regional forecast visibility. Asia-Pacific, the fastest-expanding zone at 12 % CAGR, is super-charged by China’s 14th Five-Year Plan earmarking US $2.3 bn for molecular imaging, Japan’s preferential reimbursement for multi-pet cohort studies, and India’s low-cost SPF-grade animal infrastructure.

Latin America (9 %) benefits from expanding federal oncology funds in Brazil & Mexico, rising North-South preclinical alliances, and new ISO 10993-compliant imaging cores. The Middle East & Africa (5 %) records double-digit order spikes led by Saudi Vision 2030 hospital investments, South African academic hubs upgrading to 7 T MRI, and Gulf sovereign funds courting Western imaging OEMs for localized training academies.

Competitive Landscape

The Preclinical Imaging (In-VIVO) competitive landscape is moderately consolidated, with a handful of global instrument specialists—PerkinElmer, Bruker, FUJIFILM, Mediso—controlling the majority of installed units through deep R&D pipelines and multi-regional service footprints. Below this tier, a fragmented cohort of regional vendors (Aspect Imaging, MILabs, Trifoil) competes on niche modalities or price-flexible configurations, particularly in Asia-Pacific and Eastern Europe where tender cycles favor lower-cost bids. Competitive levers revolve around securing early regulatory validation for new tracers, bundling imaging agents with hardware to raise switching costs, and negotiating multiyear maintenance contracts that offset capital budget constraints in academic cores.

To sustain differentiation, incumbents pursue serial M&A of tracer IP, form co-development pacts with CROs for GLP-compliant datasets, and refresh portfolios through modular detector upgrades rather than full-system replacement. Bruker’s vertical integration of cryogen-free magnets, PerkinElmer’s shift to fee-for-service imaging, and FUJIFILM’s hybrid optical/CT platform illustrate how scale players bundle technology, reagents, and analytics into stickier workflows. Mid-tier vendors counter by offering bench-top footprints, lower field strengths, and pay-per-use leasing to reduce total cost of ownership. Across segments, margin pressure intensifies as detector components commoditize and inflation-linked logistics erode gross profit, forcing suppliers to either localize manufacturing or absorb compliance costs tied to new EU IVDR and FDA 21 CFR Part 4 guidance.

Companies Strategy Snapshot6 items

PerkinElmer: fee-for-service imaging bundles to lock in academic cores

Bruker Corporation: vertical integration of cryogen-free magnet lines

FUJIFILM Holdings: hybrid optical/CT platform for multimodal protocols

Mediso: OEM tie-ups for PET/MRI tracer validation pipelines

MILabs B.V.: bench-top SPECT/OI to target space-constrained labs

MR Solutions: local manufacturing to mitigate logistics-driven margin erosion

Market Ecosystem

The Preclinical Imaging (In-VIVO) ecosystem spans upstream component fabrication, midstream system build-up, and downstream deployment within academic, CRO and biopharma facilities. Value originates from the iterative refinement of detectors, isotopes, optical probes and reconstruction algorithms, is captured through integrated multimodal scanner platforms, and is monetised via hardware sales, service contracts and image analytics licences.

Detector & isotope suppliers — supply scintillators, crystals and PET tracers to OEMs under GMP/ISO13485

Modality OEMs — engineer micro-PET/CT, MRI, optical and ultrasound systems into preclinical platforms

Software & analytics vendors — provide acquisition, reconstruction and quantitative workflows compliant with DICOM

System integrators — configure multimodal suites, radiation shielding and HVAC for GLP compliance

Distributors & leasing partners — finance, stock and install instruments across regional markets and core facilities

Service & calibration providers — perform IQ/OQ/PQ validation, hot-cell maintenance and dose calibrator calibrations

End-user researchers — operate scanners, generate efficacy data and transfer protocols to clinical translation teams

Adoption is governed by institutional capital budgets, radiation licensing cycles and interoperability mandates; detector shortages or isotope half-life logistics create upstream bottlenecks, while proprietary reconstruction algorithms lock users into single-vendor service contracts, raising switching costs. Regional divergence centres on tracer registration pathways—FDA self-determination in North America versus EMA centralised evaluation in Europe—altering validation timelines and local partnership structures.

Recent Industry Insights

The Preclinical Imaging (In-VIVO) industry trends over the past 18 months have been shaped by a surge in AI-driven analytics and strategic consolidation. Bruker’s late-2023 acquisition of Spectral Instruments tightened its hold on high-sensitivity optical imaging, while PerkinElmer’s integration of Improvision’s cloud-based microscopy suite accelerated AI model training on longitudinal oncology studies. In tandem, MILabs and Johns Hopkins formed an exclusive 2024 pact to co-develop a tri-modal PET-SPECT-OI platform calibrated for immuno-oncology biodistribution, slated for GLP tox labs. Regulatory momentum came when the FDA finalized guidance in Q1 2024 allowing 3R-compliant micro-dosing PET tracers to bypass traditional tox batches, trimming early-stage timelines by 30%. Venture funding flowed to startups like InviCRO’s Series C ($55 M) and Aspect Imaging’s expansion of compact 1 T MRI into APAC CROs. Users now demand self-shielded, benchtop systems with real-time reconstruction; suppliers responded with ASI’s 2024 launch of a 3 T cryogen-free preclinical scanner that halves footprint and energy draw, aligning with green lab mandates.

Analyst Overview

The Preclinical Imaging (In-VIVO) market outlook remains strongly favorable, underpinned by a 7-8 % CAGR to 2030 as biopharma outsourcing and multi-modal imaging protocols become standard. Demand is structurally ahead of supply; lead times for high-field MRI and micro-PET remain 6–9 months, giving incumbents with installed base leverage to command >65 % gross margins. Competitive intensity is moderate: four Western players hold >70 % share, but nimble Asian OEMs are closing the price–performance gap, forcing bundled service contracts rather than pure hardware sales.

Long-term, we see imaging moving from supporting to gate-keeping role in IND submissions, tightening customer stickiness. Innovation is migrating toward AI-driven 3D hybrid systems and lower-dose PET tracers; patent cliffs in 2026-28 open space for new entrants. Key risks are funding volatility in academic core facilities and increasing regulation of radiotracers, which could delay site approvals by 12–18 months. Strategics should prioritize platform plays that integrate imaging data with real-time analytics to secure durable annuities rather than one-off capital sales.

11 items

1. Executive Summary

2. Preclinical Imaging (In-VIVO) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Preclinical Imaging (In-VIVO) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Preclinical Imaging (In-VIVO) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Oncology

6.1.2. Cardio and Vascular

6.1.3. Neurology

6.1.4. Others

6.2. Global Preclinical Imaging (In-VIVO) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Equipment

6.2.2. Reagent

6.3. Global Preclinical Imaging (In-VIVO) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Preclinical Imaging (In-VIVO) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Preclinical Imaging (In-VIVO) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Preclinical Imaging (In-VIVO) Market Competition by Key Manufacturers

8.1. Global Preclinical Imaging (In-VIVO) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Preclinical Imaging (In-VIVO): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. PerkinElmer

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Bruker Corporation

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. FUJIFILM Holdings

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Mediso

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. MILabs B.V.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. MR Solutions

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Aspect Imaging

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. LI-COR Biosciences

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Trifoil Imaging

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Miltenyi Biotec

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Preclinical Imaging (In-VIVO) Market

Figure 4: Global Preclinical Imaging (In-VIVO) Market: Drivers

Figure 5: Global Preclinical Imaging (In-VIVO) Market: Challenges

Figure 6: Global Preclinical Imaging (In-VIVO) Market: Trends

Figure 7: Global Preclinical Imaging (In-VIVO) Market: Opportunity

Figure 8: Global Preclinical Imaging (In-VIVO) Market: Restraint

Figure 9: Global Preclinical Imaging (In-VIVO) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Preclinical Imaging (In-VIVO) Market Value (USD Million) By Region

Figure 15: Global Preclinical Imaging (In-VIVO) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Preclinical Imaging (In-VIVO) Market Value (USD Million) By Region

Figure 23: Global Preclinical Imaging (In-VIVO) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Preclinical Imaging (In-VIVO) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Preclinical Imaging (In-VIVO) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Preclinical Imaging (In-VIVO) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Preclinical Imaging (In-VIVO) Market Value (USD Million) By Region

Table 10: Global Preclinical Imaging (In-VIVO) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Preclinical Imaging (In-VIVO) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Preclinical Imaging (In-VIVO) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Preclinical Imaging (In-VIVO) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: PerkinElmer Basic Information And Sales Area

Table 31: PerkinElmer. Products Portfolio

Table 32: Bruker Corporation Basic Information And Sales Area

Table 33: Bruker Corporation. Products Portfolio

Table 34: FUJIFILM Holdings Basic Information And Sales Area

Table 35: FUJIFILM Holdings. Products Portfolio

Table 36: Mediso Basic Information And Sales Area

Table 37: Mediso. Products Portfolio

Table 38: MILabs B.V. Basic Information And Sales Area

Table 39: MILabs B.V.. Products Portfolio

Table 40: MR Solutions Basic Information And Sales Area

Table 41: MR Solutions. Products Portfolio

Table 42: Aspect Imaging Basic Information And Sales Area

Table 43: Aspect Imaging. Products Portfolio

Table 44: LI-COR Biosciences Basic Information And Sales Area

Table 45: LI-COR Biosciences. Products Portfolio

Table 46: Trifoil Imaging Basic Information And Sales Area

Table 47: Trifoil Imaging. Products Portfolio

Table 48: Miltenyi Biotec Basic Information And Sales Area

Table 49: Miltenyi Biotec. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Preclinical Imaging (In-VIVO) Market Value (USD Million) By Region

Table 55: Global Preclinical Imaging (In-VIVO) Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current Preclinical Imaging (In-VIVO) market size?

Preclinical Imaging (In-VIVO) market size surpassed USD 1.2 billion in 2023, propelled by expanding oncology research, heightened demand for non-invasive biomarkers, and increased R&D outsourcing by pharmaceutical firms seeking faster, cost-effective drug pipelines.

2. What is the forecasted growth rate through 2030?

Analysts project a 6.8% CAGR, lifting the market to roughly USD 1.9 billion by 2030, driven by multiplexed optical probes, AI-enabled imaging analytics, and rising preclinical outsourcing in Asia-Pacific.

3. Which factors are the primary growth drivers?

Key drivers include escalating cancer and neurodegenerative disease research, PET-MRI hybridization, funding from NIH and EU Horizon Europe, plus growing adoption of real-time imaging to reduce late-stage drug attrition.

4. What challenges restrain faster expansion?

High capital costs for multimodal systems, shortage of radiotracers, complex cross-species validation, ethical pressures to limit animal use, and stringent radiation safety compliance collectively slow market penetration.

5. Which region leads the market today?

North America commands about 42% share, anchored by NIH grants, major CRO hubs, and rapid uptake of 7T MRI and PET-MRI systems across academic centers and pharmaceutical labs.

6. Who are the top companies competing?

PerkinElmer, Bruker, Siemens Healthineers, Thermo Fisher, MILabs, MR Solutions, Mediso, Trifoil, Li-Cor, and Aspect Imaging dominate through broad multimodal portfolios, global service networks, and strategic CRO alliances.

7. What future opportunities should stakeholders watch?

Next-gen opportunities include AI-driven predictive imaging, organoid-based personalized screening, portable low-field MRI for point-of-care research, and commercialization of novel PET tracers for immuno-oncology and cell therapy tracking.

8. How is technology reshaping preclinical imaging?

High-resolution photon-counting CT, deep-learning reconstruction, real-time multispectral optoacoustic tomography, and cloud-based image repositories are slashing scan times, enhancing quantitative accuracy, and enabling decentralized collaborative studies.

9. What is the current regulatory landscape?

FDA and EMA require Good Laboratory Practice validation of imaging endpoints, while new FDA Modernization Act 2.0 encourages alternatives to animal testing, pushing vendors to develop validated in-vitro–in-vivo extrapolation software and harmonized SOPs.

Contact for Full Report

Loading report content...

Preclinical Imaging (In-VIVO) Market Growth Drivers & Forecast 2033

Market Snapshot

Preclinical Imaging (In-VIVO) Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Preclinical Imaging (In-VIVO) Segmentation

Preclinical Imaging (In-VIVO) Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Preclinical Imaging (In-VIVO) market size?

2. What is the forecasted growth rate through 2030?

3. Which factors are the primary growth drivers?

4. What challenges restrain faster expansion?

5. Which region leads the market today?

6. Who are the top companies competing?

7. What future opportunities should stakeholders watch?

8. How is technology reshaping preclinical imaging?

9. What is the current regulatory landscape?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Preclinical Imaging (In-VIVO) Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Preclinical Imaging (In-VIVO) Segmentation

Preclinical Imaging (In-VIVO) Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Preclinical Imaging (In-VIVO) market size?

2. What is the forecasted growth rate through 2030?

3. Which factors are the primary growth drivers?

4. What challenges restrain faster expansion?

5. Which region leads the market today?

6. Who are the top companies competing?

7. What future opportunities should stakeholders watch?

8. How is technology reshaping preclinical imaging?

9. What is the current regulatory landscape?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation